A few interesting snippets from the WNX investor presentation...

A few interesting snippets from the WNX investor presentation below

The share price feels like it has been held down recently, however there has still been a lot of volume in recent weeks and plenty of on screen buyers stepping up to the selling











Global expansion of Haleon into the UAE is slated to begin in the next 6 weeks. This is following the first opening purchase order for the Paracetamol Soft Gel Liquid Analgesic from Haleon for the U.K





- 126% CAGR revenue growthbetween FY22 and FY24
- 191% CAGR gross profit growthbetween FY22 and FY24
- 65.8% expansion in grossprofit margin between FY22 and FY24
- Management expectations forcontinued growth in revenue andmargins across WNX brands in FY25 asbrand awareness continues to build



- First prescriptions dispensed for medicinal cannabis brand, Wellness Life
- Target of ~50% average gross margin with its products
- The medicinal cannabis market in Australia is projected to reach USD 356.7 million in 2024, with acompound growth rate (CAGR) of 4.58% from 2024 to 2029, potentially reaching USD 446.3 million by2029